LONDON
For nearly three decades, the story medicine told itself about Alzheimer's disease went something like this: toxic proteins called amyloid and tau build up in the brain, form tangled clumps, and somehow — the details were always fuzzy — brain cells choke, wither, and die. Billions of dollars in drug development have chased those sticky protein clumps. Now, a team of scientists in London says everybody may have been missing the final, fatal step: what actually happens inside a neuron in the moments before it dies.
The answer, published this summer in Nature Communications, has a name nobody outside a handful of specialized labs had ever heard before: karyoptosis. It is being described as a genuinely new form of programmed cell death — not the same as the well-known processes of apoptosis or necrosis — and researchers say it appears to be a common, central feature of both Alzheimer's disease and frontotemporal dementia (FTD).
"This study is the culmination of a 10-year journey at King's, from when we first identified karyoptosis in a relatively rare disease to discovering that it is a common feature of dementias which affect millions of people," said Dr. Manolis Fanto, who led the research at King's College London's Institute of Psychiatry, Psychology and Neuroscience.
What Is Karyoptosis, Exactly?
Break the word down and it practically explains itself: "karyo" refers to the nucleus of a cell — the command center that holds DNA — and "ptosis" refers to a collapsing. In karyoptosis, toxic protein buildup inside a neuron triggers a specific chain reaction that destabilizes the protective envelope around the cell's nucleus. That envelope begins to shrivel and disintegrate. Once the nucleus itself starts to collapse, the cell is finished.
Researchers zeroed in on a single molecular interaction driving that collapse: a partnership between an enzyme called p38 MAP kinase and a structural protein called LaminB1. Under normal conditions, LaminB1 helps form the scaffolding of the nuclear envelope. But when toxic proteins pile up and p38 MAP kinase gets involved, that scaffolding starts to come apart.
To find this pathway, the King's team went straight to human brain tissue. Using computational algorithms, they screened roughly 3,000 individual cells taken from the brains of 28 patients who had died with either frontotemporal dementia or terminal-stage Alzheimer's. In the frontal cortex of Alzheimer's patients, 35% of cells showed clear signs of karyoptosis, compared to just 15% in healthy, aged control subjects — more than double the rate.
A Decade in the Making
Fanto's team didn't set out to solve Alzheimer's. A decade ago, they were investigating a rare genetic disease when they first spotted the telltale signature of a nucleus collapsing in a way that didn't match any known form of cell death. It took ten years of patient, incremental lab work to connect that rare-disease observation to two of the most common brain diseases on the planet.
That slow-burn origin story explains why karyoptosis has stayed under the radar, even as Alzheimer's research consumed enormous attention and funding. Most large-scale dementia research has been laser-focused on amyloid plaques and tau tangles — the visible villains that show up clearly in brain scans. Karyoptosis, by contrast, is a process happening at the microscopic, structural level of the cell's nucleus — invisible to a PET scan, and easy to miss unless you're looking with the right tools.
The Therapeutic Angle: Can You Stop It?
The King's team didn't stop at describing the problem — they tested whether they could interrupt it. In laboratory experiments using rat neurons in a dish, researchers specifically targeted the interaction between p38 MAP kinase and LaminB1, using compounds designed to block that partnership. The result: measurable reductions in the markers of karyoptosis.
"By specifically targeting the interaction between p38 MAP kinase and LaminB1, we may slow down the process of cell death, buying time for more pinpointed therapies against specific neurodegenerative diseases," Fanto explained.
Nobody on this research team is claiming they've found a cure. What they're describing is more like discovering a structural weak point in a burning building: if you can shore up that weak point, the building stays standing longer, giving other therapies more time to work. For dementia patients and their families, "more time" is not a small thing. It could mean extra years of recognizing a spouse's face, extra months of living independently, extra conversations with grandchildren before memory slips away.
Because p38 MAP kinase is an enzyme — the kind of molecular target that pharmaceutical chemists have decades of experience building drugs against — the finding opens a concrete path for drug developers. Kinase inhibitors are already a major class of medicines, most prominently in cancer treatment, meaning researchers aren't starting from zero.
Why This Matters to So Many Families
In the United States alone, an estimated 7.4 million Americans age 65 and older are currently living with clinical Alzheimer's dementia — a number projected to swell to 13.8 million by 2060 as the population ages. In the UK, Alzheimer's accounts for 60% to 80% of roughly one million dementia cases nationwide.
Frontotemporal dementia, while far less common, carries its own particular cruelty: it's the most common form of dementia in people under 60, striking in the prime of working and family lives rather than old age. Because FTD often first appears as changes in personality or language rather than obvious memory loss, it is frequently misdiagnosed for years as depression or a psychiatric condition.
The research was funded in part by Alzheimer's Research UK, whose scientists have called the discovery an important expansion of where the field should be looking for treatments. A "common feature" shared across both Alzheimer's and FTD suggests a single therapeutic strategy could potentially help patients with more than one type of dementia.
What This Means for You
If you have a family member living with Alzheimer's or frontotemporal dementia, it's important to be realistic: this is a fresh, single laboratory discovery, tested in donated human brain tissue and rat neurons in a dish, not in human clinical trials. There is no karyoptosis-blocking pill you can ask your doctor about today, and there won't be one for a good while. But for a field that has endured a decades-long string of failed Alzheimer's drug trials, a genuinely new biological mechanism — one that's druggable using existing pharmaceutical know-how — represents the kind of foundational finding that new treatment classes are eventually built on.
For now, doctors continue to recommend the same evidence-backed strategies for reducing dementia risk: managing blood pressure and cardiovascular risk factors, staying physically and socially active, protecting hearing, and getting adequate sleep. None of that changes because of one new discovery. But somewhere in a lab in London, scientists have just found a new crack in Alzheimer's armor — and after a decade quietly chasing it, they finally know exactly where to aim.
This article discusses medical research and is intended for general informational purposes only. It is not medical advice. Anyone with questions about dementia, Alzheimer's disease, or related conditions should speak with a qualified healthcare provider.
Sources: Nature Communications, King's College London, Alzheimer's Research UK, Alzheimer's Association
